Obesity Drug Discoveries: what the future holds

Publication Date	August 2007
Publisher	Espicom
Product Type	Report
Pages	116
ISBN Number	978-1-85822-294-3
Product Code	ESP00347

Buy this product or for assistance call +44 20 7060 7474

PDF £995.00$1655 | €1114

FAX Order above formats by FAX

Summary

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the anti-infective sector. The report includes unique sales forecasts by major product.

The full 400-page report, evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond. The report covers 8 key therapy areas (alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS, musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by major product. Click here for more information. This chapter is available separately.

The anti-infectives market is the fifth largest therapeutic category. We estimate that anti-infectives grossed sales of US$28.5 billion in 2005, with a further US$16 billion being derived from hospital-based use and OTC. The majority of prescription-based sales were derived from the US (around 50%) compared to 22% in Europe and Japan. However, growth in Europe at over 5% exceeded that of the US and Japan compared with around 3%.

Please Note: The publisher will not fulfil orders to a personal email address, you must supply a work or business address.

Content

Executive summaryWhat is obesity?
Defining obesity
What causes obesity?
What effects does obesity have?
- Figure 1: Effects of obesity on health
- Table 1. Relative risks of health problems associated with obesity
  - The scale of the problem
  - Prevalence of obesity
- Figure 2. Estimated global prevalence of obesity
  - Highest prevalence of obesity
    - Prevalence in the US
    - Prevalence in the UK
    - Prevalence in Europe
    - Prevalence in Asia
    - Prevalence in developing countries
- Figure 3. Percentage of households having both underweight and overweight members in seven countries
- Figure 4. Country comparison - percentage of adults with normal BMI
  - Childhood and future obesity
- Figure 5. Percentage of population that is overweight
- Figure 6. Predicted prevalence of obesity by 2025
  - The economic burden
  - US
  - UK
  - Europe
  - Developing Countries
  - The obesity therapy market
  - Competitor ratio analysis
  - Table 2. Competitor ratio analysis summary
  - Obesity management
  - Controlling energy balance
  - Achieving weight loss
  - Table 3. The benefits of a 10kg weight loss
  - Lifestyle modifications
  - Behaviour therapy
  - Pharmacotherapy
  - Surgery
  - Approved drugs for obesity management
- Table 4. History of drug treatments for obesity
- Table 5. Anti-obesity drugs approved for short-term use
- Table 6. Anti-obesity drugs approved for long-term use
  - Acomplia
  - Approval History
  - Key Markets
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
  - Further Development
  - Sales
  - Sales Forecast
- Figure 7. Acomplia reported and projected sales, 2006A-2012E (EUR million)
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - Meridia/Reductil
  - Approval History
  - Key Markets
  - Key Agreements
  - Clinical Trial Data
- Table 7. Percentage change in subject's body weight at varying doses of sibutramine
- Table 8. Health profile of subjects losing at least 5 per cent of body weight
  - Safety Issues
  - Further Development
  - Xenical/alli
  - Approval History
  - Key Markets
  - Key Agreements
  - Patent History
  - Clinical Trial Data
  - Safety Issues
  - Further Development
  - Sales
  - Sales Forecast
- Figure 8. Reported and projected sales of Xenical 2001A-2011E
  - Regulatory authority guidelines for drug approval
  - Approval for additional indications
  - Potential new drugs
- Table 9. Novel drugs in development by Phase
- Table 10. Novel drugs in development by company
  - Drugs in clinical development
- Figure 9. Estimated launch dates for profiled drugs
  - Beta3 adrenergic receptor modulators
  - Table 11. Beta3 adrenergic receptor modulators in development
  - KR P-204 (N-5984)
  - Safety Issues
  - Competitors
  - Launch Prediction
  - Cannabinoid receptor modulators
- Table 12. Cannabinoid receptor modulators in development:
  - CP-945,598
  - Safety Issues
  - Competitors
  - Launch Prediction
  - taranabant
  - Safety Issues
  - Competitors
  - Launch Prediction
  - AVE 1625
  - Safety Issues
  - Competitors
  - Launch Prediction
  - SLV 319
  - Key Agreements
  - Safety Issues
  - Competitors
  - Launch Prediction
  - Digestive inhibitors/lipid metabolism modulators
- Table 13. Digestive inhibitors/lipid metabolism modulators in development cetilistat
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
  - Further Developments
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - 869682
  - Safety Issues
  - Competitors
  - Launch Prediction
  - Histaminergic system modulators
- Table 14. Histaminergic system modulators in development
  - OBE 101
- Table 15. Properties of OBE101 and histamine compared
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
- Table 16. Adverse effects of OBE101 when compared to anti-obesity medications currently in use
  - Patent History
  - Further Development
  - Competitors
  - Launch Prediction
  - Hormone analogues
- Table 17. Hormone analogues in development pramlintide
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - liraglutide
  - Clinical Trial Data
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - obinepitide
  - Patent History
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Competitors
  - Launch Prediction
  - PYY 3-36
  - Key Agreements
  - Patent History
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Competitors
  - Launch Prediction
  - Monoamine reuptake inhibitors/5-HT receptor modulators
- Table 18. Monoamine reuptake inhibitors/5-HT receptor modulators in developmentlorcaserin
  - Patent History
  - Clinical Trial Data
- Table 19. Incidence of FDA-defined valvulopathy
  - Further Development
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - tesofensine
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Risks associated with drug development in therapeutic class
  - Neuropeptide receptor modulators
- Table 20. Neuropeptide receptor modulators in development S-2367
  - Clinical Trial Data
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - Combination drugs
- Table 21. Combination drugs in development
  - Contrave
  - Patent History
  - Clinical Trial Data
  - Further Developments
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - Qnexa
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - pramlintide+phentermine/sibutramine
  - Safety Issues
  - Competitors
  - Launch Prediction
  - Empatic
  - Patent History
  - Clinical Trial Data
- Table 22. Percentage change in body weight at week 24
  - Safety Issues
  - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
  - Recently-terminated p rogrammes
  - AMG 076
  - AOD 9604
  - Clinical Trial Data
  - CP-741952
  - CYT 009-GhrQb
  - Clinical Trial Data
  - oleoyl-estrone
  - Patent History
  - Clinical Trial Data
  - Further Development
  - PF-431499
  - The f uture of obesity treatment
  - Towards an all-encompassing cure; targeting the metabolic syndrome?
  - Recent advances and future developments
  - CD 36
  - Targeting ghrelin
  - Vaccines
  - Gene therapy
  - RNA interference
  - Conclusions
  - Sources
  - Espicom sources
  - Others